Scribe Therapeutics, Inc. — Form SCHEDULE 13D
Filed July 30, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 28/100
What the filing says
Avoro Capital Advisors LLC and Avoro Ventures LLC (reporting persons), acting through Scott Epstein and Behzad Aghazadeh, purchased 2,333,333 shares at $15/share directly from underwriters in Scribe's July 24, 2026 IPO, plus 57,905 additional shares in open market at $18.25–$22.31/share between July 24–28, 2026. Total acquisition: ~2.39M shares. Company scale cannot be determined from this filing alone.
Why this rating
IPO participation by investment firms is routine; no control threshold (5%+), governance changes, or conflicts disclosed. Material only if Avoro stake exceeds 5% of outstanding—not stated here.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.